Filing Analysis
Andrew J. Ritter resigned from the Board of Directors and all committee positions (Audit, Compensation, and Nominating/Governance) effective July 7, 2026.
🚩 Red Flags
- Simultaneous resignation from all major board committees (Audit/Compensation) can sometimes signal internal friction, though the company explicitly states there was no disagreement regarding operations or policies.
📋 Key Facts
- Effective date of resignation: July 7, 2026.
- Resigning individual: Andrew J. Ritter.
- Positions vacated: Board of Directors, Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee.
- Stated reason for departure: To pursue other time-consuming business opportunities.
Nordicus Partners Corp completed a private placement of 416,000 restricted shares of common stock to eight private investors at $2.75 per share between October and December 2025.
🚩 Red Flags
- Issuance of restricted securities that are not yet registered under the Securities Act, meaning they cannot be immediately liquidated in public markets.
📋 Key Facts
- Total shares issued: 416,000 restricted shares of common stock.
- Offering price: $2.75 per share.
- Number of investors: 8 private/accredited investors.
- Closing date for the offering: December 5, 2025.
- Exemption claimed: Section 4(a)(2) and/or Rule 506(b) and (c) of Regulation D; also Regulation S for non-U.S. persons.
Nordicus Partners Corp completed a private placement of 1,057,500 restricted shares of common stock to 54 private investors between July and September 2025. The offering was priced at $1.90 per share and conducted under Regulation D exemptions.
🚩 Red Flags
- Issuance of restricted securities often indicates a need for immediate liquidity without the cost/process of a public offering.
- The use of private placements can sometimes lead to future dilution upon registration of these shares.
📋 Key Facts
- Total shares issued: 1,057,500 restricted shares of common stock.
- Offering price: $1.90 per share.
- Number of investors: 54 private/accredited investors.
- Closing date for the offering: September 18, 2025.
- Exemption used: Section 4(a)(2) and Rule 506(b) and (c) of Regulation D.
Nordicus Partners Corp is disclosing valuation reports for its wholly owned subsidiaries, Orocidin A/S and Bio-Convert A/S, prepared by Stanton Park Advisors LLC. The purpose of these valuations is to assist the Board in evaluating fair market value as of June 30, 2025.
🚩 Red Flags
- The disclosure notes that actual results may differ materially from the financial projections used in the valuation analyses.
📋 Key Facts
- The company furnished valuation reports for subsidiaries Orocidin A/S and Bio-Convert A/S via Item 7.01.
- Valuations were performed by independent third party Stanton Park Advisors LLC.
- Valuation dates are as of June 30, 2025.
- The reports include financial projections and forward-looking statements regarding the subsidiaries' performance.
Nordicus Partners Corp announced a restructuring of its Board of Directors, including the resignation of Henrik Keller and the appointment of three new directors: Torben S. Jensen, Kim T. Mücke, and Andrew J. Ritter. The Board size has been increased from three to five members.
🚩 Red Flags
- Related-party connection: Torben Jensen and Kim Mücke are identified as major shareholders in the Company (via GK Partners ApS and AC Nordic respectively).
📋 Key Facts
- Effective August 7, 2025, Henrik Keller resigned from the Board of Directors.
- The Board size was increased from three to five members.
- New directors appointed: Torben S. Jensen, Kim T. Mücke, and Andrew J. Ritter.
- Torben Jensen and Kim Mücke will receive options for 25,000 shares each at $1.90/share.
- Andrew Ritter will receive options for 50,000 shares at $1.90/share.
- All new directors will receive an annual cash retainer of $10,000.
Nordicus Partners Corp completed a private placement of 35,000 restricted shares of common stock to non-U.S. persons at $4.00 per share. The offering was conducted under Regulation D and Regulation S exemptions.
🚩 Red Flags
- Private placement of restricted shares often indicates a need for immediate liquidity in micro-cap companies.
- The issuance is to 'non-U.S. Persons,' which can sometimes complicate future domestic liquidity if not managed correctly, though standard for international capital raising.
📋 Key Facts
- Commenced private placement on June 5, 2025.
- Issued 35,000 restricted shares of common stock to a private investor on June 16, 2025.
- Offering price was $4.00 per share.
- Total proceeds from this specific issuance: $140,000.
- Issuance conducted under Section 4(a)(2) and Rule 506(b)/(c) of Regulation D.
- Shares were offered to non-U.S. Persons via Regulation S.
Nordicus Partners Corp announced amendments to the employment and consulting agreements for its CEO, Henrik Rouf, and CFO, Bennett J. Yankowitz, effective July 1, 2025.
🚩 Red Flags
- Multiple amendments (third amendment) to compensation agreements for top executives may indicate ongoing restructuring or instability in executive terms.
📋 Key Facts
- CEO Henrik Rouf entered into a third amended employment agreement with a base salary of $360,000 per year for a one-year term starting July 1, 2025.
- CFO Bennett J. Yankowitz entered into a third amended consulting agreement with a base salary of $120,000 per year for a one-year term starting July 1, 2025.
- The Board of Directors approved these amendments on June 30, 2025.
Nordicus Partners Corp announced the closing of a private offering of 54,000 restricted shares of common stock issued to two private investors in April and May 2025. The shares were sold at a price of $5.00 per share.
🚩 Red Flags
- Issuance of restricted securities often indicates a need for immediate capital without the ability to use public markets.
- The shares are unregistered and subject to transfer restrictions.
📋 Key Facts
- Total shares issued: 54,000 restricted shares of common stock.
- Issuance period: April and May 2025; closing determined on June 11, 2025.
- Price per share: $5.00.
- Recipients: Two private investors (accredited investors).
- Exemption used: Section 4(a)(2) and/or Rule 506(b) and (c) of Regulation D, as well as Regulation S for non-U.S. persons.
The Company is providing a presentation regarding its wholly owned subsidiary, Bio-Convert A/S, in accordance with Regulation FD. The information is intended for analysts and investors and does not contain new financial projections beyond previously disclosed data.
📋 Key Facts
- Company to present information regarding its wholly owned subsidiary, Bio-Convert A/S, on or after April 1, 2025.
- The presentation (Exhibit 99.1) is furnished under Item 7.01 and is not considered 'filed' for purposes of Section 18 of the Exchange Act.
- Information in the presentation does not provide new financial condition data beyond the fiscal quarter ended September 30, 2024.
Nordicus Partners Corp filed an 8-K to furnish a presentation regarding its wholly owned subsidiary, Orocidin A/S. The filing is made pursuant to Regulation FD and contains summary information intended for analysts and investors.
📋 Key Facts
- The company will present information regarding its wholly owned subsidiary, Orocidin A/S, on or after March 6, 2025.
- Information provided in the presentation is limited to financial conditions up to the fiscal quarter ended September 30, 2024.
- The filing includes Exhibit 99.1 containing the investor presentation slides.
The company is furnishing a presentation to analysts and investors under Regulation FD. The information provided in the presentation is intended for informational purposes regarding the company's financial condition as of September 30, 2024.
📋 Key Facts
- Company furnished a presentation (Exhibit 99.1) pursuant to Item 7.01.
- The presentation contains summary information intended for analysts and investors.
- Financial data in the presentation is current only up to the fiscal quarter ended September 30, 2024.
Nordicus Partners Corp issued a warrant to GK Partners ApS on December 30, 2024, allowing the investor to purchase 1,000,000 shares of common stock. The transaction was conducted via an unregistered sale relying on Section 4(a)(2) and Regulation S exemptions.
🚩 Red Flags
- Unregistered sale of equity securities (Item 3.02), which can lead to future dilution for existing shareholders.
- Warrant exercise price is tied to VWAP, potentially creating a floating strike price that could impact volatility upon exercise.
📋 Key Facts
- Issued a warrant to GK Partners ApS (Denmark-based private investor) on December 30, 2024.
- Warrant allows for the purchase of 1,000,000 shares of common stock.
- The warrant expires on December 31, 2025.
- Exercise price is the greater of $8.91 or the VWAP on the trading date preceding the expiration notice.
- The sale was conducted without sales commissions and relies on Section 4(a)(2) and Regulation S exemptions.
Nordicus Partners Corp entered into two consulting agreements on November 27, 2024, to secure investor relations services. These include a cash-based agreement with Harbor Access LLC and an equity-based agreement with ESG Advisor Group, L.L.C.
🚩 Red Flags
- Equity-based compensation to consultants (ESG Advisor Group) can lead to significant dilution for existing shareholders.
- Performance-based milestones for share issuance (volume and price targets) may create misaligned incentives between the company and the consultant regarding stock price volatility.
📋 Key Facts
- Entered into a Consulting Agreement with Harbor Access LLC for $8,000 per month through November 30, 2025.
- Entered into a Professional Relations and Consulting Agreement with ESG Advisor Group, L.L.C. involving the issuance of 61,500 restricted shares of common stock.
- ESG shares vest in tranches: 15,300 shares after 45 days, followed by up to 11 monthly tranches of 4,200 shares.
- ESG is eligible for additional share bonuses based on volume and trading price milestones.
- The equity issuance was conducted via exemptions under Section 4(a)(2), Rule 506(b), or Rule 701.
Nordicus Partners Corp completed the acquisition of Orocidin A/S, a Danish stock corporation, making it a 100% owned subsidiary. The transaction was executed via a stock-for-stock swap where the company issued 200,000 restricted shares to acquire 5.34% of Orocidin's outstanding capital stock.
🚩 Red Flags
- The acquisition was completed via the issuance of unregistered, restricted common stock.
- Transaction involves an exchange of equity for a minority stake that results in 100% ownership, suggesting potentially complex valuation or restructuring mechanics.
📋 Key Facts
- Acquisition date: November 12, 2024.
- Target: Orocidin A/S (Danish stock corporation).
- Consideration: Issuance of 200,000 restricted shares of Nordicus Partners Corp common stock.
- Assets acquired: 29,663 shares of Orocidin capital stock (representing 5.34% of Orocidin's outstanding shares).
- Resulting ownership: Orocidin is now a 100% owned subsidiary of Nordicus Partners Corp.
Nordicus Partners Corp acquired 100% of Bio-Convert ApS, a Danish stock corporation, in an all-stock transaction. The company issued 12,000,000 restricted shares of its common stock to the sellers of Bio-Convert.
🚩 Red Flags
- Significant dilution potential due to the issuance of 12,000,000 new restricted shares.
- Unregistered securities: The shares issued to the sellers have not been registered under the Securities Act and are subject to legends/transfer restrictions.
📋 Key Facts
- Acquisition date: November 12, 2024.
- Target: Bio-Convert ApS (Danish stock corporation).
- Assets acquired: 595,400 shares representing 100% of Bio-Convert's outstanding capital stock.
- Consideration: Issuance of 12,000,000 restricted shares of Nordicus Partners Corp common stock.
- The shares issued were not registered under the Securities Act and are subject to transfer restrictions.
Nordicus Partners Corporation announced the resignation of Christian Hill-Madsen from its Board of Directors, effective June 3, 2024. Peter Severin has been appointed as his replacement and will serve as Chairman of the Board.
🚩 Red Flags
- Potential conflict of interest: The departing director remains Chairman of a major subsidiary (Orocidin A/S) that was recently acquired via a share exchange with the parent company.
📋 Key Facts
- Christian Hill-Madsen resigned from the Board of Directors on June 3, 2024.
- Peter Severin appointed to replace Hill-Madsen and serve as Chairman of the Board.
- The Board approved new director compensation: $20,000 per annum for the Chairman and $10,000 per annum for other Directors.
- Hill-Madsen will remain Chairman of Orocidin A/S, a company in which Nordicus recently acquired a 95% stake.
Nordicus Partners Corp completed a significant acquisition of 95.0% of Orocidin A/S, a Danish stock corporation, on May 13, 2024. The transaction was funded through the issuance of 38,000,000 restricted shares of Nordicus common stock to the sellers.
🚩 Red Flags
- Massive dilution: The issuance of 38,000,000 restricted shares represents a significant expansion of the share count which may heavily dilute existing shareholders.
- Unregistered securities: The 38 million shares issued are 'restricted' and not registered under the Securities Act, meaning they cannot be easily liquidated by the sellers in the public market immediately.
📋 Key Facts
- Acquired 525,597 shares of Orocidin A/S, representing 95.0% of its outstanding capital stock.
- Consideration paid: Issuance of 38,000,000 restricted shares of Nordicus Partners Corp common stock.
- Transaction consummated on May 13, 2024.
- The issuance was made to 'Sellers' who are described as shareholders of Orocidin A/S.
- The new shares were issued under exemptions from registration (Section 4(a)(2), Rule 506(b), or Regulation S).